Specific language disorder

Summary

Specific language disorder (MONDO:0016226) is a disease and 2 clinical trials. Top therapeutic interventions include dexamethasone. A subtype of specific learning disability — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	specific language disorder
Mondo ID	MONDO:0016226
MeSH	D000080888
Orphanet	211053
UMLS	C4553954
MedGen	1631585
Is cancer (heuristic)	no

Also known as: dysphasia · specific language disorder

Data availability: 3 cell lines.

Disease family

This is a subtype of specific learning disability. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › specific learning disability › specific language disorder

Related subtypes (1): non-verbal learning disability

Subtypes (2): familial developmental dysphasia, childhood apraxia of speech

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dexamethasone	Phase 3 (in late-stage trials)
Methylprednisolone	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03308084	PHASE3	COMPLETED	Use of Local Intraoperative Steroid in MIS TLIF
NCT02872870	Not specified	COMPLETED	Developmental Language Difficulties: Behavioural and Electrophysiological Studies

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXAMETHASONE	4	1